Published in Vasc Health Risk Manag on January 01, 2008
Bariatric endocrinology: principles of medical practice. Int J Endocrinol (2014) 0.91
Treating diabetes and prediabetes by focusing on obesity management. Curr Diab Rep (2009) 0.87
Combinations of drugs in the Treatment of Obesity. Pharmaceuticals (Basel) (2010) 0.77
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79
Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care (2004) 75.82
Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser (2000) 70.59
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med (2001) 56.11
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care (1997) 49.11
Banting lecture 1988. Role of insulin resistance in human disease. Diabetes (1988) 33.22
Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care (1997) 23.95
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med (2004) 17.91
The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet (1963) 16.71
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 15.32
Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med (2001) 14.48
Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care (2001) 14.03
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 11.13
Lifetime risk for diabetes mellitus in the United States. JAMA (2003) 10.33
Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes (1997) 8.96
U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes (1995) 8.95
Economic costs of diabetes in the US in 2002. Diabetes Care (2003) 8.92
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA (2003) 8.47
Systematic review: an evaluation of major commercial weight loss programs in the United States. Ann Intern Med (2005) 8.00
Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med (1995) 7.62
The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest (1999) 7.35
Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care (1994) 7.11
Diabetes trends in the U.S.: 1990-1998. Diabetes Care (2000) 7.05
Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol (2004) 6.78
The Southall Diabetes Survey: prevalence of known diabetes in Asians and Europeans. Br Med J (Clin Res Ed) (1985) 6.36
Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med (2002) 6.32
Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet (1998) 6.17
Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes (2002) 6.05
Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med (2005) 5.54
Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2003) 5.38
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care (2004) 5.34
Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study. Diabetologia (1991) 5.32
Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes (1999) 5.10
Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care (2000) 4.64
Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. Int J Obes (Lond) (2006) 4.45
Walking compared with vigorous physical activity and risk of type 2 diabetes in women: a prospective study. JAMA (1999) 4.43
Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation (2001) 4.32
Dietary patterns, meat intake, and the risk of type 2 diabetes in women. Arch Intern Med (2004) 4.27
Dietary patterns and risk for type 2 diabetes mellitus in U.S. men. Ann Intern Med (2002) 4.19
Coffee consumption and risk of type 2 diabetes: a systematic review. JAMA (2005) 4.14
Effect of fatty acids on glucose production and utilization in man. J Clin Invest (1983) 4.00
Carbohydrates, dietary fiber, and incident type 2 diabetes in older women. Am J Clin Nutr (2000) 3.93
Regional adiposity and morbidity. Physiol Rev (1994) 3.85
Effectiveness of community health workers in the care of persons with diabetes. Diabet Med (2006) 3.66
Diabetes mellitus in the Pima Indians: incidence, risk factors and pathogenesis. Diabetes Metab Rev (1990) 3.64
Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA (1999) 3.56
Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev (1998) 3.20
Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med (1987) 2.99
The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil (2004) 2.79
Long-term (5-year) effects of a reduced-fat diet intervention in individuals with glucose intolerance. Diabetes Care (2001) 2.43
Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab (2003) 2.41
Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation (2005) 2.39
Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract (2005) 2.38
Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men. BMJ (1995) 2.31
Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Care (2004) 2.24
Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens (2003) 2.24
Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev (2001) 2.22
Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes (1999) 2.14
A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care (2005) 2.01
Whole-grain intake and the risk of type 2 diabetes: a prospective study in men. Am J Clin Nutr (2002) 1.96
Effects of traditional and western environments on prevalence of type 2 diabetes in Pima Indians in Mexico and the U.S. Diabetes Care (2006) 1.96
Estimated number of adults with prediabetes in the US in 2000: opportunities for prevention. Diabetes Care (2003) 1.84
Prevention or delay of type 2 diabetes. Diabetes Care (2004) 1.73
Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care (2001) 1.72
Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension (2003) 1.71
Community-based lifestyle interventions to prevent type 2 diabetes. Diabetes Care (2003) 1.70
The effect of short periods of caloric restriction on weight loss and glycemic control in type 2 diabetes. Diabetes Care (1998) 1.68
The burden of overweight and obesity in the Asia-Pacific region. Obes Rev (2007) 1.67
Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care (1998) 1.58
The role of TNF-alpha in insulin resistance. Endocrine (2004) 1.53
A prospective study of drinking patterns in relation to risk of type 2 diabetes among men. Diabetes (2001) 1.52
Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med (2000) 1.51
Mode of action of orlistat. Int J Obes Relat Metab Disord (1997) 1.51
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept (2005) 1.45
Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients. Diabetes Care (2004) 1.42
Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation (2004) 1.42
Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res (2000) 1.42
Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care (2004) 1.41
Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care (2002) 1.35
Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia (2004) 1.33
Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective. Int J Technol Assess Health Care (2007) 1.30
Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care (2007) 1.24
Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients? Expert Rev Cardiovasc Ther (2006) 1.23
Pharmacologic prevention or delay of type 2 diabetes mellitus. Ann Pharmacother (2004) 1.19
Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care (2002) 1.18
Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity: a 4-year case-controlled study. Diabetes Care (2005) 1.18
Preventing type II diabetes mellitus. J Clin Pharmacol (2004) 1.16
Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers. Am J Physiol Gastrointest Liver Physiol (2001) 1.12
Plasma fatty acids, adiposity, and variance of skeletal muscle insulin resistance in type 2 diabetes mellitus. J Clin Endocrinol Metab (2001) 1.10
The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes. Arch Intern Med (2002) 1.10
Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetes. Am J Clin Nutr (2003) 1.07
The effect of estrogen use on levels of glucose and insulin and the risk of type 2 diabetes in american Indian postmenopausal women : the strong heart study. Diabetes Care (2002) 1.06
Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs (2003) 1.05
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med (2015) 11.05
Effects of weight loss on asthma control in obese patients with severe asthma. Eur Respir J (2013) 2.25
Fasting breath hydrogen concentration in short bowel syndrome patients with colon incontinuity before and after antibiotic therapy. Nutrition (2004) 2.01
Thirty-day morbidity and mortality of the laparoscopic ileal interposition associated with sleeve gastrectomy for the treatment of type 2 diabetic patients with BMI <35: an analysis of 454 consecutive patients. World J Surg (2011) 1.52
Prospective randomized controlled trial comparing 2 versions of laparoscopic ileal interposition associated with sleeve gastrectomy for patients with type 2 diabetes with BMI 21-34 kg/m(2). Surg Obes Relat Dis (2009) 1.51
Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol (2007) 1.39
Weight loss improves neurovascular and muscle metaboreflex control in obesity. Am J Physiol Heart Circ Physiol (2003) 1.28
Surgical treatment of type 2 diabetes in patients with BMI below 35: mid-term outcomes of the laparoscopic ileal interposition associated with a sleeve gastrectomy in 202 consecutive cases. J Gastrointest Surg (2012) 1.10
Improvement in insulin sensitivity and β-cell function following ileal interposition with sleeve gastrectomy in type 2 diabetic patients: potential mechanisms. J Gastrointest Surg (2011) 1.05
Abnormal neurovascular control during sympathoexcitation in obesity. Obes Res (2003) 1.02
Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner. Diabetes Technol Ther (2011) 1.01
Diet and exercise training restore blood pressure and vasodilatory responses during physiological maneuvers in obese children. Circulation (2005) 1.00
Effect of zinc supplementation on serum leptin levels and insulin resistance of obese women. Biol Trace Elem Res (2006) 0.98
Gly16 + Glu27 beta2-adrenoceptor polymorphisms cause increased forearm blood flow responses to mental stress and handgrip in humans. J Appl Physiol (1985) (2005) 0.97
Effects of nasal continuous positive airway pressure treatment on oxidative stress and adiponectin levels in obese patients with obstructive sleep apnea. Respiration (2009) 0.97
Body composition, visceral fat distribution and fat oxidation in postmenopausal women using oral or transdermal oestrogen. Maturitas (2003) 0.95
Is a diagnosis of metabolic syndrome applicable to children? J Pediatr (Rio J) (2010) 0.95
Intra-abdominal thickness by ultrasonography to predict risk factors for cardiovascular disease and its correlation with anthropometric measurements. Metabolism (2002) 0.92
Effects of perilipin (PLIN) gene variation on metabolic syndrome risk and weight loss in obese children and adolescents. J Clin Endocrinol Metab (2008) 0.90
Impact of adiposity on immunological parameters. Arq Bras Endocrinol Metabol (2009) 0.89
Improvement of insulin resistance and reduction of cardiovascular risk among obese patients with type 2 diabetes with the duodenojejunal bypass liner. Obes Surg (2011) 0.89
Blood pressure measurement in obese patients: comparison between upper arm and forearm measurements. Blood Press Monit (2004) 0.87
Calcium intake and metabolic bone disease after eight years of Roux-en-Y gastric bypass. Obes Surg (2008) 0.87
Bariatric surgery reverses natural killer (NK) cell activity and NK-related cytokine synthesis impairment induced by morbid obesity. Obes Surg (2011) 0.87
Prevalence of subclinical hypothyroidism in a morbidly obese population and improvement after weight loss induced by Roux-en-Y gastric bypass. Obes Surg (2005) 0.87
[Obesity and coronary artery disease: role of vascular inflammation]. Arq Bras Cardiol (2010) 0.85
[Metabolic Syndrome in professional truck drivers who work on Highway BR-116 within the area of São Paulo City - Régis Bittencourt]. Arq Bras Endocrinol Metabol (2008) 0.85
Lipid peroxidation in bariatric candidates with nonalcoholic fatty liver disease (NAFLD) -- preliminary findings. Obes Surg (2005) 0.85
Binge eating symptoms, diet composition and metabolic characteristics of obese children and adolescents. Appetite (2007) 0.84
Follow-up of Roux-en-Y gastric bypass patients at 5 or more years postoperatively. Obes Surg (2007) 0.83
[Case report: recently diagnosed celiac disease as aggravating factor of osteoporosis in an old woman]. Arq Bras Endocrinol Metabol (2006) 0.83
Basal energy expenditure and diet- induced modifications to thermogenesis in short bowel syndrome. Clin Nutr (2005) 0.82
[Characterization of metabolic resting rate and proposal of a new equation for a female Brazilian population]. Arq Bras Endocrinol Metabol (2010) 0.82
[Obstructive sleep apnea contribution to oxidative stress in obesity]. Arq Bras Endocrinol Metabol (2008) 0.82
Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications. Expert Opin Drug Saf (2015) 0.82
Investigational therapies in the treatment of obesity. Expert Opin Investig Drugs (2006) 0.81
Effect of surgery-induced weight loss on immune function. Expert Rev Gastroenterol Hepatol (2008) 0.81
Multidisciplinary approach to morbidly obese patients undergoing surgical treatment by adjustable gastric banding. Rev Col Bras Cir (2010) 0.81
Effect of gastric bypass on spontaneous growth hormone and ghrelin release profiles. Obesity (Silver Spring) (2006) 0.81
Long-term pharmacotherapy for obesity in elderly patients: a retrospective evaluation of medical records from a specialized obesity outpatient clinic. Drugs Aging (2010) 0.80
[Role of zinc in insulin resistance]. Arq Bras Endocrinol Metabol (2004) 0.80
Systemic hypertension, diabetes mellitus, and dyslipidemia in relation to body mass index: evaluation of a Brazilian population. Rev Hosp Clin Fac Med Sao Paulo (2004) 0.79
Impact on dyslipidemia of the laparoscopic ileal interposition associated to sleeve gastrectomy in type 2 diabetic patients. J Gastrointest Surg (2010) 0.79
[Metabolic profile according to leptin levels in obese patients]. Arq Bras Endocrinol Metabol (2007) 0.78
Metformin in normal-weight hirsute women with polycystic ovary syndrome with normal insulin sensitivity. Gynecol Endocrinol (2007) 0.78
Surgical treatment of morbid obesity: mid-term outcomes of the laparoscopic ileal interposition associated to a sleeve gastrectomy in 120 patients. Obes Surg (2011) 0.78
Fixed-dose combination of phentermine-topiramate for the treatment of obesity. Expert Rev Clin Pharmacol (2013) 0.78
Lack of mutations in the leptin receptor gene in severely obese children. Arq Bras Endocrinol Metabol (2012) 0.78
Associations between a common variant near the MC4R gene and serum triglyceride levels in an obese pediatric cohort. Endocrine (2015) 0.76
Results of biliopancreatic diversion in two patients with Prader-Willi syndrome. Obes Surg (2005) 0.76
The N363S polymorphism in the glucocorticoid receptor gene: effects on visceral fat assessed by abdominal computed tomography. Arq Bras Endocrinol Metabol (2009) 0.76
Pharmacological treatment of obesity. Arq Bras Endocrinol Metabol (2006) 0.76
[Hormonal axes in obesity: cause or effect?]. Arq Bras Endocrinol Metabol (2007) 0.76
Body composition alterations, energy expenditure and fat oxidation in elderly males suffering from prostate cancer, pre and post orchiectomy. Clinics (Sao Paulo) (2009) 0.76
Bupropion/naltrexone fixed-dose combination for the treatment of obesity. Drugs Today (Barc) (2011) 0.76
[Analysis of resting metabolic rate evaluated by indirect calorimetry in obese women with low and high caloric intake]. Arq Bras Endocrinol Metabol (2008) 0.76
Changes in neuropsychological tests and brain metabolism after bariatric surgery. J Clin Endocrinol Metab (2014) 0.76
Why are anti-obesity drugs stigmatized? Expert Opin Drug Saf (2014) 0.75
[The Internet as a tool to treat an overweight population]. Arq Bras Endocrinol Metabol (2005) 0.75
THE MASTICATORY SYSTEM OF THE OBESE: CLINICAL AND ELECTROMYOGRAPHIC EVALUATION. Int J Orofacial Myology (2014) 0.75
[Obese children lipid profile: effects of hypocaloric diet and aerobic physical exercise]. Arq Bras Endocrinol Metabol (2006) 0.75
[Therapeutical approach of obesity in Prader-Willi Syndrome]. Arq Bras Endocrinol Metabol (2007) 0.75
[Recent progress and novel perspectives on obesity pharmacotherapy]. Arq Bras Endocrinol Metabol (2010) 0.75
Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery. Rev Col Bras Cir (2013) 0.75